The study will evaluate different types of beta-blockers, including selective beta-blockers, beta-blockers combined with thiazides, and alpha-beta blockers. These medications will be given by mouth for up to 6 months. The purpose of the study is to understand how beta-blocker treatment impacts the outcomes of patients receiving valve replacement.

The research will track various health outcomes in patients for up to one year after their valve replacement procedure. This includes monitoring for heart-related events, such as heart failure, stroke, and heart rhythm problems. The study will also track how many patients need pacemakers or require hospital readmission during this time period.

The purpose of the study is to investigate the effect of angiotensin receptor blockers on mild to moderate aortic stenosis. Over the course of 24 months, participants will take the medication or placebo and undergo regular check-ups. These check-ups will include tests like echocardiography, which uses sound waves to create images of the heart, and magnetic resonance imaging (MRI), which uses magnets and radio waves to take detailed pictures of the heart. These tests will help doctors see how the heart and its valves are functioning and if there are any changes in the heart’s structure or function.

Throughout the study, doctors will monitor the rate at which the aortic valve narrows and any changes in the heart’s size and shape. They will also look at how well the heart is pumping blood and measure certain markers in the blood that can indicate heart health. The study will help determine if Losartan Potassium can slow down the progression of aortic stenosis and improve heart function compared to the placebo.

The research aims to determine if medications that fight tissue scarring can help reduce heart muscle scarring after the valve replacement procedure. The study will use two medications: spironolactone and dihydralazine. Some patients will receive spironolactone alone, some will receive both medications together, and others will receive standard care without these additional medications.

The study will last 12 months, during which patients will take their assigned medications daily. To measure the amount of heart muscle scarring, patients will undergo cardiac magnetic resonance imaging (CMR) before their valve replacement procedure and again one year later. This imaging test uses a special dye called gadolinium to show areas of scarring in the heart muscle.

The purpose of the study is to explore the relationship between inflammation and the development of conduction disorders, which are problems with the heart’s electrical system that can occur after the valve replacement procedure. Participants will undergo PET scans to assess inflammation levels and will be monitored for any conduction disorders during their hospital stay and for up to six months afterward. This includes checking for issues like complete or partial heart block, which can affect how the heart beats.

Throughout the study, participants may also be evaluated for the need for a pacemaker, a device that helps control abnormal heart rhythms. The study aims to provide insights into how inflammation might influence the heart’s electrical pathways and potentially lead to better management of patients undergoing valve replacement procedures. The findings could help improve understanding and treatment of conduction disorders in patients with aortic stenosis.

The purpose of the study is to evaluate whether dapagliflozin can help improve heart muscle function, reduce heart muscle thickening, and enhance kidney function. The study will also look at whether the medication can decrease the chances of heart failure getting worse and reduce the risk of death. Participants in the study will either receive dapagliflozin or a placebo, which is a substance with no active medication, to compare the effects.

Participants will be monitored over a period of time to assess changes in their heart and kidney health. The study will track various health indicators, such as heart muscle thickness and kidney function, to determine the effectiveness of dapagliflozin. The goal is to gather information that could lead to better treatment options for people with aortic stenosis who have undergone the TAVR procedure.

Participants in the study will be randomly assigned to receive either Jardiance or a placebo. A placebo is a substance with no active medication, used to compare the effects of the actual drug. The study will monitor changes in the heart’s left ventricle over a period of 12 months after the aortic valve replacement. This will be done using imaging techniques like computed tomography (CT) and echocardiography, which are methods to take detailed pictures of the heart. The study will also look at other factors such as heart function and levels of a heart-related protein called NT-proBNP.

The trial aims to provide valuable information on whether Jardiance can offer additional benefits to patients recovering from aortic valve replacement surgery. By understanding these effects, the study hopes to improve treatment options and outcomes for individuals with aortic stenosis who undergo this type of heart surgery.

The purpose of the study is to determine if this iron treatment can improve the quality of life and exercise capacity in patients who are undergoing a procedure called Transcatheter Aortic Valve Implantation (TAVI). TAVI is a minimally invasive procedure used to replace the narrowed aortic valve. Participants in the study will receive either the iron treatment or a placebo. Over the course of the study, participants will be monitored for changes in their quality of life, ability to exercise, and cognitive function, which refers to mental processes like thinking and memory.

The study will last for several months, during which participants will undergo various assessments, including questionnaires and a walking test, to evaluate their progress. The main goal is to see if the iron treatment can help improve the overall well-being and physical abilities of those with severe aortic stenosis and iron deficiency. The results will help determine if this treatment could be beneficial for similar patients in the future.

Participants in the study will be randomly assigned to receive either Ticagrelor or Aspirin as a single antiplatelet treatment. Antiplatelet medications help prevent blood clots, which can be a concern after heart procedures. The study will monitor participants for 12 months to observe any significant health events, such as heart attacks, strokes, or bleeding. These events are collectively referred to as Net Adverse Clinical Events (NACE), which include all-cause mortality, transient ischemic attack (TIA) or stroke, myocardial infarction, progressive angina, valve thrombosis, claudication, acute limb ischemia, and any bleeding.

The trial aims to provide valuable information on which medication might be more beneficial for patients after TAVI. Participants will be closely monitored throughout the study period to ensure their safety and to gather data on the effectiveness of the treatments. The study will help determine the best approach to managing patients with severe aortic stenosis who have undergone TAVI, potentially improving outcomes and quality of life for these individuals.

Participants in the study will receive either routine or selective doses of protamine sulfate, which is used to counteract the effects of blood thinners and reduce bleeding. Another substance, sodium chloride, will also be used as a solution for injection or infusion during the study. The study will monitor the risk of cardiovascular mortality or bleeding within 30 days after the TAVI procedure, following specific criteria known as VARC-3. The goal is to determine which method of administering protamine sulfate is more effective in reducing these risks.

The study will take place over a period, with participants being observed for any bleeding complications, changes in hemoglobin levels, and other related outcomes. The trial will also assess the length of hospital stay after the procedure, the need for blood transfusions, and any major vascular complications. The findings from this study could help improve treatment strategies for patients undergoing TAVI, potentially leading to better outcomes and reduced risks of bleeding and other complications.

The purpose of the study is to determine the most effective and safe treatment strategy for preventing complications such as blood clots and bleeding after TAVI. Participants in the study will be randomly assigned to receive either one of the anticoagulants or acetylsalicylic acid. Some participants may receive a placebo, which looks like the real medication but does not contain any active ingredients. The study will last for up to 12 months, during which participants will take the assigned medication and attend regular follow-up visits to monitor their health and any side effects.

Throughout the study, researchers will closely observe the participants to assess the effectiveness of the treatments in preventing complications and improving overall health outcomes. The study will also evaluate the safety of these medications by monitoring for any adverse effects, such as bleeding or other health issues. The findings from this trial will help doctors make informed decisions about the best treatment options for patients with aortic stenosis who undergo TAVI.